Effect of Fenugreek Seed Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion (NCT07056712)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Men and women between 30 and 60 years old.
2. Diagnosis of Metabolic Syndrome (MS) according to the International Diabetes Federation (IDF) criteria. Waist circumference ≥90 cm in men and ≥80 cm in women, plus the presence of two or more of the following criteria:
3. Fasting glucose ≥100 mg/dL or previous diagnosis of type 2 diabetes.
4. Systolic Blood Pressure ≥130 mmHg.
5. Diastolic Blood Pressure ≥85 mmHg.
6. Triglycerides ≥150 mg/dL.
7. HDL cholesterol \<40 mg/dL in men and \<50 mg/dL in women.
8. Body Mass Index between 25.0 and 34.9 kg/m².
9. Stable weight during the 3 months prior to the start of the study (weight variation less than 10%).
10. Not receiving pharmacological treatment for any component of MS, insulin sensitivity, and/or insulin secretion.
11. Signed informed consent form. Non-Inclusion Criteria:
12. Suspected or confirmed pregnancy.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• Instituto de Terapéutica Experimental y Clínica (INTEC), Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara. — Guadalajara, Jalisco

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.